EART yields 0.60% · PFE yields 6.13%● Live data
📍 PFE pulled ahead of the other in Year 9
Combined, EART + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of EART + PFE for your $10,000?
DMAT tracks an index of global stocks that produce metals and other raw materials essential to the expansion of disruptive technologies. Disruptive Materials Companies derive at least 50% of their revenues from the exploration, mining, production and/or enhancement of one or more of 10 materials categories that include Rare Earth Materials, Lithium, Copper, Carbon Fiber, etc. Stocks not meeting the revenue requirements are considered after review and recognized as Pre-Revenue Disruptive Materials Companies. In the case of Lithium, stocks with associated revenue between 25-50% are also eligible as Diversified Lithium Companies. The fund uses a natural language processing algorithm to identify and rank stocks. The five highest-ranked Disruptive Materials and Pre-Revenue Disruptive Materials Companies per materials category are selected. The fund employs a modified market-cap weighting scheme for diversification. The index is reconstituted and rebalanced semi-annually.
Full EART Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.